Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Current Deferred Revenue (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Current Deferred Revenue data on record, last reported at $5.8 million in Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 81.77% year-over-year to $5.8 million; the TTM value through Sep 2025 reached $5.8 million, down 81.77%, while the annual FY2024 figure was $19.0 million, 24.05% up from the prior year.
  • Current Deferred Revenue reached $5.8 million in Q3 2025 per STOK's latest filing, down from $8.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $31.6 million in Q3 2024 and bottomed at $5.8 million in Q3 2025.
  • Average Current Deferred Revenue over 4 years is $14.8 million, with a median of $13.5 million recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 261.9% in 2024, then tumbled 81.77% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $14.9 million in 2022, then increased by 2.88% to $15.3 million in 2023, then increased by 24.05% to $19.0 million in 2024, then tumbled by 69.65% to $5.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $5.8 million in Q3 2025, $8.7 million in Q2 2025, and $18.2 million in Q1 2025.